Assertio Therapeutics, Inc. について
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
本部251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
設立2018
状態アクティブ
特許1 件の特許
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
法的情報
| 正式名称 | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20GLEIF で見る ↗ |
| 登記住所 | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| 状態 | アクティブ |
出典: GLEIF · 2026年10月16日 に更新
連絡先・リンク
所在地
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
あなたの企業ですか?
このページを無料で申請すると、ロゴ、製品、写真、求人を追加し、レビューに返信できます。
このページを申請